Skip to main content

PASP Calculation on Echocardiography: ASE 2025 Guide

 

Echo for beginners

PASP Calculation on Echocardiography: ASE 2025 Guide, Interpretation, Pitfalls, and Clinical Significance


Pulmonary artery systolic pressure (PASP) is one of the most frequently reported measurements on transthoracic echocardiography (TTE). It provides a non-invasive estimate of pulmonary artery pressure and serves as an important screening tool for pulmonary hypertension (PH). However, PASP should never be interpreted in isolation. The latest American Society of Echocardiography (ASE) guidelines emphasize a multiparametric, probability-based approach rather than relying solely on a numerical PASP value.


This article reviews the latest ASE recommendations, explains how PASP is calculated, discusses common pitfalls, and highlights how to interpret PASP accurately in daily clinical practice.


────────────────────────


What is PASP?


Pulmonary artery systolic pressure (PASP) represents the peak systolic pressure within the pulmonary artery. In the absence of pulmonic valve stenosis or right ventricular outflow tract obstruction, PASP is considered equal to the right ventricular systolic pressure (RVSP).


Because the right ventricle ejects directly into the pulmonary artery, RV systolic pressure closely reflects pulmonary artery systolic pressure under normal circumstances.


────────────────────────


Why is PASP Important?


PASP estimation helps clinicians:


• Screen patients for pulmonary hypertension


• Evaluate unexplained dyspnea


• Assess right ventricular pressure overload


• Monitor disease progression


• Evaluate response to pulmonary hypertension therapy


• Risk stratify patients with heart failure, congenital heart disease, valvular heart disease, and chronic lung disease


Although echocardiography is an excellent screening modality, right heart catheterization remains the gold standard for diagnosing pulmonary hypertension.


────────────────────────


ASE 2025 Formula for PASP Calculation


The calculation remains straightforward.


PASP = 4 × (TR Peak Velocity)² + Right Atrial Pressure (RAP)


Where:


TR Peak Velocity = Peak velocity of tricuspid regurgitation jet (m/s)


RAP = Estimated right atrial pressure derived from inferior vena cava (IVC) size and respiratory collapse.


────────────────────────


Step 1: Measure Peak TR Velocity


Continuous-wave Doppler is used to record the highest measurable tricuspid regurgitation jet.


Important recommendations:


• Use multiple acoustic windows


• Apical four-chamber view


• RV inflow view


• Parasternal short-axis


• Subcostal view (when required)


Always use the highest measurable TR velocity.


Incorrect alignment with the jet results in underestimation of PASP.


────────────────────────


Step 2: Calculate TR Pressure Gradient


Apply the modified Bernoulli equation:


Pressure Gradient = 4 × (TR Velocity)²


Examples:


TR velocity = 2.8 m/s


Gradient = 31 mmHg


TR velocity = 3.5 m/s


Gradient = 49 mmHg


TR velocity = 4.0 m/s


Gradient = 64 mmHg


────────────────────────


Step 3: Estimate Right Atrial Pressure (RAP)


ASE recommends estimating RAP using IVC diameter and inspiratory collapse.


IVC ≤2.1 cm with >50% collapse


RAP = 3 mmHg


IVC >2.1 cm with <50% collapse


RAP = 15 mmHg


Intermediate findings


RAP = 8 mmHg


When IVC assessment is unreliable, RAP estimation should be interpreted cautiously.


────────────────────────


Step 4: Calculate PASP


Example:


TR velocity = 3.4 m/s


Pressure gradient


= 4 × (3.4²)


= 46 mmHg


Estimated RAP = 8 mmHg


PASP = 46 + 8


= 54 mmHg


────────────────────────


Normal PASP


Normal PASP is generally considered:


≤35 mmHg


Values above this should prompt careful clinical assessment.


────────────────────────


PASP Severity


Although many echocardiography reports still categorize PASP as mild, moderate, or severe, ASE no longer recommends making clinical decisions based solely on these cutoffs.


Traditional echocardiographic ranges are:


Normal


≤35 mmHg


Mild elevation


36–50 mmHg


Moderate elevation


51–70 mmHg


Severe elevation


«70 mmHg»


Older literature often used:


Severe PASP


«60 mmHg»


However, this threshold is not part of current ASE or ESC/ERS guideline recommendations.


────────────────────────


ASE 2025: Probability-Based Interpretation


The major shift in recent ASE recommendations is moving away from severity labels based solely on PASP.


Instead, clinicians should estimate the probability of pulmonary hypertension.


TR Velocity ≤2.8 m/s


Low probability


TR Velocity 2.9–3.4 m/s


Intermediate probability


TR Velocity >3.4 m/s


High probability


This assessment must always be integrated with additional echocardiographic findings.


────────────────────────


Additional Echocardiographic Findings That Increase the Likelihood of Pulmonary Hypertension


Right ventricular enlargement


Reduced RV systolic function


Right atrial enlargement


Interventricular septal flattening


Pulmonary artery dilatation


Dilated IVC with poor inspiratory collapse


Short pulmonary acceleration time


Abnormal RV outflow Doppler profile


Presence of pericardial effusion


The more abnormal findings that are present, the greater the likelihood of clinically significant pulmonary hypertension.


────────────────────────


Common Causes of Elevated PASP


Left-sided heart disease


Heart failure


Mitral valve disease


Aortic valve disease


Pulmonary arterial hypertension


Chronic thromboembolic pulmonary hypertension


Chronic lung disease


Obstructive sleep apnea


Congenital heart disease


Pulmonary embolism


High cardiac output states


────────────────────────


Causes of Incorrect PASP Estimation


Several factors may lead to inaccurate PASP estimation.


Poor TR Doppler signal


Suboptimal Doppler alignment


Very severe tricuspid regurgitation


Absent measurable TR jet


Incorrect RAP estimation


Mechanical ventilation


RV outflow tract obstruction


Pulmonic stenosis


These limitations explain why PASP should never be interpreted without considering the overall clinical picture.


────────────────────────


When Should PASP Not Be Reported?


ASE advises caution when:


No measurable TR jet is present.


TR Doppler envelope is incomplete.


Signal quality is poor.


Severe Dopacardiographic artifacts prevent reliable measurement.


Reporting an inaccurate PASP can be more misleading than not reporting it.


────────────────────────


When is Right Heart Catheterization Needed?


Echocardiography estimates the probability of pulmonary hypertension.


Right heart catheterization is recommended when:


Diagnosis remains uncertain


Pulmonary hypertension-specific therapy is being considered


Advanced pulmonary hypertension is suspected


Pre-operative assessment requires confirmation


Clinical findings disagree with echocardiography


Right heart catheterization remains the definitive diagnostic test.


────────────────────────


Key Clinical Pearls


• PASP equals RVSP unless pulmonic stenosis or RVOT obstruction is present.


• Always use the highest measurable TR velocity.


• Estimate RAP using IVC diameter and respiratory collapse.


• PASP is an estimate, not a definitive diagnosis.


• Avoid interpreting PASP without assessing right ventricular size and function.


• TR velocity is often more useful than PASP alone.


• Current ASE guidelines recommend a probability-based approach rather than strict PASP severity categories.


• Confirmation with right heart catheterization is essential whenever clinically indicated.


────────────────────────


Take-Home Message


PASP estimation remains one of the most valuable components of echocardiography for screening pulmonary hypertension. The latest ASE recommendations reinforce that PASP should be interpreted as part of a comprehensive right heart assessment rather than as an isolated number. A high-quality TR Doppler signal, accurate estimation of right atrial pressure, and integration with other echocardiographic findings provide the most reliable assessment. When pulmonary hypertension is suspected or treatment decisions depend on the diagnosis, right heart catheterization remains the gold standard.


For more cardiology articles and professional echocardiography resources, visit:


drmusmanjaved.com


Comments

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...